• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

ChAdOx1 载体疫苗（AZD2816）在临床前研究中诱导针对 SARS-CoV-2 变体（B.1.351）和其他关注变体的强烈免疫原性。

The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies.

机构信息

Nuffield Department of Medicine, The Jenner Institute, University of Oxford, ORCRB, Roosevelt Drive, Oxford OX3 7DQ, United Kingdom.

Nuffield Department of Medicine, The Jenner Institute, University of Oxford, ORCRB, Roosevelt Drive, Oxford OX3 7DQ, United Kingdom.

出版信息

EBioMedicine. 2022 Mar;77:103902. doi: 10.1016/j.ebiom.2022.103902. Epub 2022 Feb 26.

DOI:10.1016/j.ebiom.2022.103902
PMID:35228013
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8881183/
Abstract

BACKGROUND

There is an ongoing global effort to design, manufacture, and clinically assess vaccines against SARS-CoV-2. Over the course of the ongoing pandemic a number of new SARS-CoV-2 virus isolates or variants of concern (VoC) have been identified containing mutations in key proteins.

METHODS

In this study we describe the generation and preclinical assessment of a ChAdOx1-vectored vaccine (AZD2816) which expresses the spike protein of the Beta VoC (B.1.351).

FINDINGS

We demonstrate that AZD2816 is immunogenic after a single dose. When AZD2816 is used as a booster dose in animals primed with a vaccine encoding the original spike protein (ChAdOx1 nCoV-19/ [AZD1222]), an increase in binding and neutralising antibodies against Beta (B.1.351), Gamma (P.1) and Delta (B.1.617.2) is observed following each additional dose. In addition, a strong and polyfunctional T cell response was measured all booster regimens.

INTERPRETATION

Real world data is demonstrating that one or more doses of licensed SARS-CoV-2 vaccines confer reduced protection against hospitalisation and deaths caused by divergent VoC, including Omicron. Our data support the ongoing clinical development and testing of booster vaccines to increase immunity against highly mutated VoC.

FUNDING

This research was funded by AstraZeneca with supporting funds from MRC and BBSRC.

摘要

背景

目前全球正在努力设计、制造和临床评估针对 SARS-CoV-2 的疫苗。在大流行期间，已经发现了许多含有关键蛋白突变的新 SARS-CoV-2 病毒分离株或关注变体（VOC）。

方法

在这项研究中，我们描述了一种基于 ChAdOx1 的疫苗（AZD2816）的产生和临床前评估，该疫苗表达 Beta VOC（B.1.351）的刺突蛋白。

结果

我们证明了 AZD2816 在单次给药后具有免疫原性。当 AZD2816 用作预先用编码原始刺突蛋白的疫苗（ChAdOx1 nCoV-19/[AZD1222]）免疫的动物的加强剂量时，在每次额外剂量后，针对 Beta（B.1.351）、Gamma（P.1）和 Delta（B.1.617.2）的结合和中和抗体增加。此外，还测量了所有加强方案中的强烈和多功能 T 细胞反应。

解释

现实世界的数据表明，一种或多种已批准的 SARS-CoV-2 疫苗剂量对由不同 VOC 引起的住院和死亡的保护作用降低，包括奥密克戎。我们的数据支持正在进行的加强疫苗的临床开发和测试，以提高对高度突变 VOC 的免疫力。

资金

这项研究由阿斯利康资助，英国医学研究理事会和生物技术和生物科学研究理事会提供支持资金。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/24e3/8886015/df8265d11336/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/24e3/8886015/8f04af81db3d/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/24e3/8886015/b0cdd5b5bf90/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/24e3/8886015/747e29c469ac/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/24e3/8886015/dfbd4d3579e5/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/24e3/8886015/df8265d11336/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/24e3/8886015/8f04af81db3d/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/24e3/8886015/b0cdd5b5bf90/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/24e3/8886015/747e29c469ac/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/24e3/8886015/dfbd4d3579e5/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/24e3/8886015/df8265d11336/gr5.jpg

相似文献

1
The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies.ChAdOx1 载体疫苗（AZD2816）在临床前研究中诱导针对 SARS-CoV-2 变体（B.1.351）和其他关注变体的强烈免疫原性。
EBioMedicine. 2022 Mar;77:103902. doi: 10.1016/j.ebiom.2022.103902. Epub 2022 Feb 26.
2
Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study.β 变异株 COVID-19 疫苗 AZD2816 和 AZD1222（ChAdOx1 nCoV-19）作为初免接种程序在巴西、南非、波兰和英国的未曾接种过疫苗的成年人中的免疫原性和安全性：一项随机、部分双盲、2/3 期非劣效免疫桥接研究。
Lancet Microbe. 2024 Aug;5(8):100863. doi: 10.1016/S2666-5247(24)00078-8. Epub 2024 Jun 12.
3
Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland.AZD2816（针对 B.1.351 变异株的 COVID-19 疫苗）和 AZD1222（ChAdOx1 nCoV-19）作为已接种人群的第三剂加强针的免疫原性和安全性：在英国和波兰进行的一项多中心、随机、部分双盲、2/3 期非劣效性免疫桥接研究
Lancet Microbe. 2023 Nov;4(11):e863-e874. doi: 10.1016/S2666-5247(23)00177-5. Epub 2023 Sep 29.
4
ChAdOx1 nCoV-19 (AZD1222) or nCoV-19-Beta (AZD2816) protect Syrian hamsters against Beta Delta and Omicron variants.ChAdOx1 nCoV-19（阿斯利康）或 nCoV-19-Beta（阿斯利康）可保护叙利亚仓鼠免受 Beta Delta 和奥密克戎变异株的侵害。
Nat Commun. 2022 Aug 8;13(1):4610. doi: 10.1038/s41467-022-32248-6.
5
Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.巴西两剂科兴新冠疫苗（CoronaVac）既往接种者中异源与同源加强接种 COVID-19 疫苗（RHH-001）：一项四期、非劣效性、单盲、随机研究。
Lancet. 2022 Feb 5;399(10324):521-529. doi: 10.1016/S0140-6736(22)00094-0. Epub 2022 Jan 21.
6
Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial.在接种一剂灭活全病毒 COVID-19 疫苗（VLA2001）加强针后针对原始株、Delta 株和奥密克戎株变异病毒的安全性和免疫原性：COV-COMPARE 随机对照 3 期试验开放标签扩展的中期分析。
J Infect. 2023 Sep;87(3):242-254. doi: 10.1016/j.jinf.2023.06.022. Epub 2023 Jul 3.
7
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.腺病毒载体新冠疫苗（ChAdOx1 nCoV-19）对严重急性呼吸综合征冠状病毒 2 （SARS-CoV-2）的安全性和免疫原性：一项 1/2 期、单盲、随机对照临床试验的初步报告。
Lancet. 2020 Aug 15;396(10249):467-478. doi: 10.1016/S0140-6736(20)31604-4. Epub 2020 Jul 20.
8
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.在年轻和老年成年人中进行的一次单盲、随机、对照、2/3 期试验中，观察 ChAdOx1 nCoV-19 疫苗在初免-加强免疫方案中的安全性和免疫原性（COV002）。
Lancet. 2021 Dec 19;396(10267):1979-1993. doi: 10.1016/S0140-6736(20)32466-1. Epub 2020 Nov 19.
9
Humoral immune response after different SARS-CoV-2 vaccination regimens.不同 SARS-CoV-2 疫苗接种方案后的体液免疫应答。
BMC Med. 2022 Jan 21;20(1):31. doi: 10.1186/s12916-021-02231-x.
10
SARS-CoV-2 S1 Subunit Booster Vaccination Elicits Robust Humoral Immune Responses in Aged Mice.SARS-CoV-2 S1 亚单位加强疫苗在老年小鼠中引发强烈的体液免疫应答。
Microbiol Spectr. 2023 Jun 15;11(3):e0436322. doi: 10.1128/spectrum.04363-22. Epub 2023 May 10.

引用本文的文献

1
Comprehensive review of preclinical evaluation strategies for COVID-19 vaccine candidates: assessing immunogenicity, toxicology, and safety profiles.新冠病毒疫苗候选物临床前评估策略的全面综述：评估免疫原性、毒理学和安全性概况。
Iran J Microbiol. 2025 Feb;17(1):1-18. doi: 10.18502/ijm.v17i1.17796.
2
A Narrative Overview of Coronavirus Infection: Clinical Signs and Symptoms, Viral Entry and Replication, Treatment Modalities, and Management.冠状病毒感染的叙述性概述：临床体征和症状、病毒进入和复制、治疗方式和管理。
Curr Top Med Chem. 2024;24(21):1883-1916. doi: 10.2174/0115680266296095240529114058.
3
Preclinical immune efficacy against SARS-CoV-2 beta B.1.351 variant by MVA-based vaccine candidates.

本文引用的文献

1
Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses.致命的 COVID-19 结局与针对与地方性冠状病毒共享表位的抗体反应有关。
JCI Insight. 2022 Jul 8;7(13):e156372. doi: 10.1172/jci.insight.156372.
2
SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.严重急性呼吸综合征冠状病毒2型奥密克戎变异株B.1.1.529可导致广泛的中和抗体反应逃逸。
Cell. 2022 Feb 3;185(3):467-484.e15. doi: 10.1016/j.cell.2021.12.046. Epub 2022 Jan 4.
3
Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
基于 MVA 的候选疫苗对 SARS-CoV-2 beta B.1.351 变异株的临床前免疫效力。
Front Immunol. 2023 Dec 12;14:1264323. doi: 10.3389/fimmu.2023.1264323. eCollection 2023.
4
ChAdOx1 COVID vaccines express RBD open prefusion SARS-CoV-2 spikes on the cell surface.ChAdOx1新冠疫苗在细胞表面表达RBD开放预融合型严重急性呼吸综合征冠状病毒2刺突蛋白。
iScience. 2023 Sep 12;26(10):107882. doi: 10.1016/j.isci.2023.107882. eCollection 2023 Oct 20.
5
The End or a New Era of Development of SARS-CoV-2 Virus: Genetic Variants Responsible for Severe COVID-19 and Clinical Efficacy of the Most Commonly Used Vaccines in Clinical Practice.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）病毒发展的终结还是新时代：导致重症冠状病毒病（COVID-19）的基因变体以及临床实践中最常用疫苗的临床疗效
Vaccines (Basel). 2023 Jun 30;11(7):1181. doi: 10.3390/vaccines11071181.
6
Immunogenicity and protective efficacy of SARS-CoV-2 mRNA vaccine encoding secreted non-stabilized spike in female mice.编码分泌型非稳定 Spike 的 SARS-CoV-2 mRNA 疫苗在雌性小鼠中的免疫原性和保护效力。
Nat Commun. 2023 Apr 21;14(1):2309. doi: 10.1038/s41467-023-37795-0.
7
COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection.COVID-19 疫苗更新：疫苗效力、SARS-CoV-2 变体、加强针、不良反应以及保护的免疫相关性。
J Biomed Sci. 2022 Oct 15;29(1):82. doi: 10.1186/s12929-022-00853-8.
8
Viral vector and nucleic acid vaccines against COVID-19: A narrative review.针对新型冠状病毒肺炎的病毒载体疫苗和核酸疫苗：一篇综述。
Front Microbiol. 2022 Aug 31;13:984536. doi: 10.3389/fmicb.2022.984536. eCollection 2022.
9
ChAdOx1 nCoV-19 (AZD1222) or nCoV-19-Beta (AZD2816) protect Syrian hamsters against Beta Delta and Omicron variants.ChAdOx1 nCoV-19（阿斯利康）或 nCoV-19-Beta（阿斯利康）可保护叙利亚仓鼠免受 Beta Delta 和奥密克戎变异株的侵害。
Nat Commun. 2022 Aug 8;13(1):4610. doi: 10.1038/s41467-022-32248-6.
10
Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern.铝佐剂-CpG 诱导的受体结合域重组蛋白对 SARS-CoV-2 关切变异株产生广泛保护作用。
Vaccine. 2022 Jun 9;40(26):3655-3663. doi: 10.1016/j.vaccine.2022.05.007. Epub 2022 May 8.
巴西两剂科兴新冠疫苗（CoronaVac）既往接种者中异源与同源加强接种 COVID-19 疫苗（RHH-001）：一项四期、非劣效性、单盲、随机研究。
Lancet. 2022 Feb 5;399(10324):521-529. doi: 10.1016/S0140-6736(22)00094-0. Epub 2022 Jan 21.
4
Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa.BNT162b2疫苗在南非针对奥密克戎变异株的有效性
N Engl J Med. 2022 Feb 3;386(5):494-496. doi: 10.1056/NEJMc2119270. Epub 2021 Dec 29.
5
Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum.免疫后血清对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）奥密克戎B.1.1.529变体的中和作用降低。
Lancet. 2022 Jan 15;399(10321):234-236. doi: 10.1016/S0140-6736(21)02844-0. Epub 2021 Dec 20.
6
Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants.异源感染和疫苗接种塑造了针对 SARS-CoV-2 变体的免疫。
Science. 2022 Jan 14;375(6577):183-192. doi: 10.1126/science.abm0811. Epub 2021 Dec 2.
7
Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice.变异的 SARS-CoV-2 mRNA 疫苗在小鼠中作为初级或加强系列疫苗具有广泛的中和作用。
Vaccine. 2021 Dec 17;39(51):7394-7400. doi: 10.1016/j.vaccine.2021.11.001. Epub 2021 Nov 8.
8
Beta RBD boost broadens antibody-mediated protection against SARS-CoV-2 variants in animal models.贝塔 RBD 增强剂拓宽了抗体介导的针对 SARS-CoV-2 变体的保护作用，在动物模型中得到了验证。
Cell Rep Med. 2021 Nov 16;2(11):100450. doi: 10.1016/j.xcrm.2021.100450. Epub 2021 Oct 23.
9
Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine-boosted nonhuman primates.mRNA-1273 疫苗加强针可预防非人类灵长类动物感染 SARS-CoV-2 Beta 变体。
Science. 2021 Dec 10;374(6573):1343-1353. doi: 10.1126/science.abl8912. Epub 2021 Oct 21.
10
Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2.SARS-CoV-2 小鼠模型中病毒清除和保护的适应性免疫决定因素。
Sci Immunol. 2021 Oct 15;6(64):eabl4509. doi: 10.1126/sciimmunol.abl4509. Epub 2021 Sep 2.